Skip to main content

Mind Medicine (MindMed), Inc. (MNMD)

2020-03-03: MNMD · IEX Real-Time Price · USD
2.45 0.01 (0.41%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap901.71M
Revenue (ttm)n/a
Net Income (ttm)-35.34M
Shares Out368.05M
EPS (ttm)-0.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,235,155
Open2.48
Previous Close2.44
Day's Range2.41 - 2.48
52-Week Range0.38 - 5.77
Betan/a
Analystsn/a
Price Target5.00 (+104.1%)
Est. Earnings Daten/a

About MNMD

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

IndustryBiotechnology
IPO DateMar 3, 2020
Employees22
Stock Exchange2020-03-03
Ticker SymbolMNMD
Full Company Profile

News

MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is plea...

1 week ago - PRNewsWire

7 Penny Stocks Waiting on The FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPl...

1 week ago - InvestorPlace

MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleas...

1 week ago - PRNewsWire

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agit...

NEW YORK, Sept. 2, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ...

2 weeks ago - PRNewsWire

MindMed Teams Up With Forian To Improve Real-World Evidence Data To Help Psychiatric Patients

Psychedelics-focused medicines company Mind Medicine Inc. (NASDAQ:MNMD), (NEO: MMED) announced Tuesday that it has teamed up with Forian Inc. (NASDAQ:FORA), a provider of evidence-based support for more...

Other symbols:FORA
3 weeks ago - Benzinga

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agre...

Other symbols:FORA
3 weeks ago - PRNewsWire

MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has join...

1 month ago - PRNewsWire

Push the Boundaries of DMT Therapy with Mind Medicine

Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.

1 month ago - InvestorPlace

MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline

The psychedelics-focused medicines company MindMed (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), announced its second-quarter financial results Friday with a net and comprehensive loss of $36 million, which c...

1 month ago - Benzinga

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Divers...

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results...

1 month ago - PRNewsWire

10 Penny Stocks to Buy to Create a $500 Portfolio

These ten low-priced penny stocks have ample room to gain, making them each worthy of a small, speculative investment. The post 10 Penny Stocks to Buy to Create a $500 Portfolio appeared first on Invest...

1 month ago - InvestorPlace

No Matter How the Pandemic Rolls, Mind Medicine Will Prevail

While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling. The post No Matter How the Pandemic Rolls, Mind Medicine Will Prevail ap...

1 month ago - InvestorPlace

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

NEW YORK, Aug. 10, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D.

1 month ago - PRNewsWire

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and ...

1 month ago - PRNewsWire

7 Stocks to Buy if You Think Alternative Therapies Are the Future

Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Futur...

Other symbols:CMPSGTBIFSTIM
1 month ago - InvestorPlace

MindMed Interim CEO on the growing competition in psychedelics industry

This segment originally aired on July 29, 2021. Robert Barrow, MindMed Interim CEO, joins Yahoo Finance to discuss then transition in MindMed's CEO, future outlook for the company and the psychedelics i...

1 month ago - Yahoo Finance

MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects

Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such as ayahuasca, giving promising results in the quest for alternative treatments fo...

1 month ago - Benzinga

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

NEW YORK, July 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 c...

1 month ago - PRNewsWire

Mind Medicine Has More Obstacles Than Opportunities

MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business. The post Mind Medicine Has More Obstacles Than Opportunities appea...

1 month ago - InvestorPlace

MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

NEW YORK, July 12, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Execu...

2 months ago - PRNewsWire

7 Top-Rated Pharmaceutical Companies to Invest In for July

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In ...

2 months ago - InvestorPlace

MindMed Stock Is Overvalued and Too Risky to Own

MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about. The post MindMed Stock Is Overvalued and Too Risky to Own appeared fir...

2 months ago - InvestorPlace

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

NEW YORK, July 8, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helpi...

2 months ago - PRNewsWire

The MindMed Psychedelic Revolution Will Take Years to Come to Fruition

MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.

2 months ago - InvestorPlace

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More

Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group initiated coverage of companies in the psychedelics space, giving a bullish B...

Other symbols:ENVB
2 months ago - Benzinga